# Aardvark Therapeutics, Inc.: financial statements, quarterly

AARD · Nasdaq · CIK 1774857 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aard.md) · [Financials](/companies/aard/financials.md) · [Filings](/companies/aard/filings.md) · [Insiders](/companies/aard/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aard/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [0.0](/filings/0000950170-25-071560.md) | [0.0 d](/filings/0000950170-25-108116.md) | [0.0 d](/filings/0001193125-25-280260.md) | [0.0 d](/filings/0001193125-26-119770.md) | [0.0](/filings/0001193125-26-210675.md) | [0.0 d](/filings/0001193125-26-344987.md) |
| Research and development | $m | [1.2](/filings/0000950170-25-071560.md) | [4.0](/filings/0000950170-25-108116.md) | [4.1](/filings/0001193125-25-280260.md) | [8.1 d](/filings/0001193125-26-119770.md) | [7.8](/filings/0001193125-26-210675.md) | [13.1](/filings/0001193125-26-344987.md) | [13.7](/filings/0001193125-25-280260.md) | [14.3 d](/filings/0001193125-26-119770.md) | [16.6](/filings/0001193125-26-210675.md) | [10.5](/filings/0001193125-26-344987.md) |
| Operating income | $m | [(2.2)](/filings/0000950170-25-071560.md) | [(6.1)](/filings/0000950170-25-108116.md) | [(5.1)](/filings/0001193125-25-280260.md) | [(9.5) d](/filings/0001193125-26-119770.md) | [(10.5)](/filings/0001193125-26-210675.md) | [(15.8)](/filings/0001193125-26-344987.md) | [(17.7)](/filings/0001193125-25-280260.md) | [(18.7) d](/filings/0001193125-26-119770.md) | [(22.5)](/filings/0001193125-26-210675.md) | [(15.1)](/filings/0001193125-26-344987.md) |
| Net income | $m | [(2.2)](/filings/0000950170-25-071560.md) | [(5.4)](/filings/0000950170-25-108116.md) | [(4.2)](/filings/0001193125-25-280260.md) | [(8.8) d](/filings/0001193125-26-119770.md) | [(9.3)](/filings/0001193125-26-210675.md) | [(14.4)](/filings/0001193125-26-344987.md) | [(16.3)](/filings/0001193125-25-280260.md) | [(17.6) d](/filings/0001193125-26-119770.md) | [(21.6)](/filings/0001193125-26-210675.md) | [(14.4)](/filings/0001193125-26-344987.md) |
| Diluted EPS | $ per share | [(0.55)](/filings/0000950170-25-071560.md) | [(1.37)](/filings/0000950170-25-108116.md) | [(1.05)](/filings/0001193125-25-280260.md) | not reported | [(0.71)](/filings/0001193125-26-210675.md) | [(0.66)](/filings/0001193125-26-344987.md) | [(0.75)](/filings/0001193125-25-280260.md) | not reported | [(0.99)](/filings/0001193125-26-210675.md) | [(0.66)](/filings/0001193125-26-344987.md) |
| Basic EPS | $ per share | [(0.55)](/filings/0000950170-25-071560.md) | [(1.37)](/filings/0000950170-25-108116.md) | [(1.05)](/filings/0001193125-25-280260.md) | not reported | [(0.71)](/filings/0001193125-26-210675.md) | [(0.66)](/filings/0001193125-26-344987.md) | [(0.75)](/filings/0001193125-25-280260.md) | not reported | [(0.99)](/filings/0001193125-26-210675.md) | [(0.66)](/filings/0001193125-26-344987.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | [61.6](/filings/0001193125-26-119770.md) | [26.5](/filings/0000950170-25-071560.md) | [26.0](/filings/0000950170-25-108116.md) | [39.3](/filings/0001193125-25-280260.md) | [47.1](/filings/0001193125-26-344987.md) | [62.4](/filings/0001193125-26-210675.md) | [73.8](/filings/0001193125-26-344987.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [74.1](/filings/0001193125-26-119770.md) | [155](/filings/0000950170-25-071560.md) | [145](/filings/0000950170-25-108116.md) | [129](/filings/0001193125-25-280260.md) | [112](/filings/0001193125-26-344987.md) | [93.6](/filings/0001193125-26-210675.md) | [80.7](/filings/0001193125-26-344987.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [77.5](/filings/0001193125-26-119770.md) | [157](/filings/0000950170-25-071560.md) | [147](/filings/0000950170-25-108116.md) | [133](/filings/0001193125-25-280260.md) | [117](/filings/0001193125-26-344987.md) | [98.6](/filings/0001193125-26-210675.md) | [81.5](/filings/0001193125-26-344987.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [4.9](/filings/0001193125-26-119770.md) | [6.0](/filings/0000950170-25-071560.md) | [10.3](/filings/0000950170-25-108116.md) | [10.7](/filings/0001193125-25-280260.md) | [10.5](/filings/0001193125-26-344987.md) | [11.6](/filings/0001193125-26-210675.md) | [6.4](/filings/0001193125-26-344987.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [5.4](/filings/0001193125-26-119770.md) | [6.3](/filings/0000950170-25-071560.md) | [10.6](/filings/0000950170-25-108116.md) | [10.9](/filings/0001193125-25-280260.md) | [10.5](/filings/0001193125-26-344987.md) | [11.6](/filings/0001193125-26-210675.md) | [6.7](/filings/0001193125-26-344987.md) |
| Shareholders' equity | $m | [(34.8)](/filings/0001193125-26-119770.md) | [(36.9)](/filings/0000950170-25-108116.md) | [(42.3)](/filings/0001193125-25-280260.md) | [(46.2)](/filings/0001193125-25-280260.md) | [(54.6)](/filings/0001193125-26-344987.md) | [151](/filings/0001193125-26-344987.md) | [137](/filings/0001193125-26-344987.md) | [122](/filings/0001193125-25-280260.md) | [107](/filings/0001193125-26-344987.md) | [87.0](/filings/0001193125-26-344987.md) | [74.8](/filings/0001193125-26-344987.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.2)](/filings/0000950170-25-071560.md) | [(4.2) d](/filings/0000950170-25-108116.md) | [(4.0) d](/filings/0001193125-25-280260.md) | [(7.7) d](/filings/0001193125-26-119770.md) | [(11.4)](/filings/0001193125-26-210675.md) | [(9.8) d](/filings/0001193125-26-344987.md) | [(16.1) d](/filings/0001193125-25-280260.md) | [(16.8) d](/filings/0001193125-26-119770.md) | [(18.9)](/filings/0001193125-26-210675.md) | [(17.6) d](/filings/0001193125-26-344987.md) |
| Capital expenditure | $m | [0.0](/filings/0000950170-25-071560.md) | [0.1 d](/filings/0000950170-25-108116.md) | [0.0 d](/filings/0001193125-25-280260.md) | [0.0 d](/filings/0001193125-26-119770.md) | [0.0](/filings/0000950170-25-071560.md) | [0.1 d](/filings/0001193125-26-344987.md) | [0.0 d](/filings/0001193125-25-280260.md) | [0.0 d](/filings/0001193125-26-119770.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [4.0](/filings/0000950170-25-071560.md) | [4.0](/filings/0000950170-25-108116.md) | [4.0](/filings/0001193125-25-280260.md) | [13.2](/filings/0001193125-26-210675.md) | [21.7](/filings/0001193125-26-344987.md) | [21.7](/filings/0001193125-25-280260.md) | [21.8](/filings/0001193125-26-210675.md) | [21.8](/filings/0001193125-26-344987.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,884,846 at 2026-07-31, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344987.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.